AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39638602 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 95
Study 39638602 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 95
Study 39638782 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pembrolizumab with bevacizumab and oral cyclophosphamide
Number of subjects: 40
Study 39639088 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg daily)
Number of subjects: 39
Study 39639088 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA monitoring
Number of subjects: 39
Study 39639184 — intervention group
Group type: EXPERIMENTAL
Intervention: CPMRx mobile application (electronic monitoring blister pack plus mobile application)
Number of subjects: 98
Study 39639184 — intervention group
Group type: COMPARATOR
Intervention: Control group (electronic monitoring blister pack only)
Number of subjects: 98
Study 39639281 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pregnancy LDL/HDL ratio
Number of subjects: 767
Study 39639281 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pregnancy TC/HDL ratio
Number of subjects: 767
Study 39639281 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of elevated LDL/HDL ratio
Number of subjects: 767
Study 39639281 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline age, fasting plasma glucose, and LH
Number of subjects: 767
Study 39639282 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative writing intervention combined with standard treatment
Number of subjects: 300
Study 39639282 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 300
Study 39639282 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot RCT for participants aged 18-35 with schizophrenia spectrum disorders
Number of subjects: 300
Study 39639285 — intervention group
Group type: COMPARATOR
Intervention: Clinic
Number of subjects: 240
Study 39639285 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-WIC
Number of subjects: 240
Study 39639285 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-RDN
Number of subjects: 240
Study 39639285 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-WIC-RDN
Number of subjects: 240
Study 39639285 — intervention group
Group type: COMPARATOR
Intervention: Clinic and Clinic-RDN
Number of subjects: 240
Study 39639285 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-WIC and Clinic-WIC-RDN
Number of subjects: 240
Study 39639285 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary endpoints
Number of subjects: 240
Study 39639285 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation outcome measures
Number of subjects: 240
Study 39639405 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week caloric restriction combined with strength and HIIT training
Number of subjects: 23
Study 39639560 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 18
Study 39639560 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal carbon dioxide removal (ECCO)
Number of subjects: 18
Study 39639890 — intervention group
Group type: EXPERIMENTAL
Intervention: Swept-source OCT angiography (SS-OCTA) metrics
Number of subjects: 60
Study 39639890 — intervention group
Group type: EXPERIMENTAL
Intervention: OCTA examinations and microaneurysm counting using CFP
Number of subjects: 60
Study 39639915 — intervention group
Group type: EXPERIMENTAL
Intervention: Method B (catheter advanced after retracting integral stylet by 6 cm)
Number of subjects: 25
Study 39639915 — intervention group
Group type: COMPARATOR
Intervention: Method A (catheter advanced with integral stylet extending along its entire length)
Number of subjects: 25
Study 39639915 — intervention group
Group type: EXPERIMENTAL
Intervention: Method B (pilot study in patients)
Number of subjects: 25
Study 39639945 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral smartphone data (passively sensed)
Number of subjects: 131
Study 39639945 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower step count
Number of subjects: 131
Study 39639945 — intervention group
Group type: EXPERIMENTAL
Intervention: Slower walking rate
Number of subjects: 131
Study 39639945 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower normalized location entropy
Number of subjects: 131
Study 39639945 — intervention group
Group type: EXPERIMENTAL
Intervention: More time at home
Number of subjects: 131
Study 39639945 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower distances traveled
Number of subjects: 131
Study 39640074 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 165
Study 39640075 — intervention group
Group type: EXPERIMENTAL
Intervention: Uchasingihwan (UCSGH) 2.5 g granule three times a day for six weeks
Number of subjects: 74
Study 39640075 — intervention group
Group type: COMPARATOR
Intervention: loxoprofen 60 mg tablet three times a day for six weeks
Number of subjects: 74
Study 39640075 — intervention group
Group type: EXPERIMENTAL
Intervention: Uchasingihwan (UCSGH)
Number of subjects: 74
Study 39640075 — intervention group
Group type: COMPARATOR
Intervention: loxoprofen
Number of subjects: 74
Study 39640185 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish version of the Medial Tibial Stress Syndrome score (MTSS-Tr)
Number of subjects: 48
Study 39640185 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish version of the 36-Item Short-Form Survey (SF-36-Tr)
Number of subjects: 48
Study 39640185 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analog scale (VAS) for pain
Number of subjects: 48
Study 39640219 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise programme (HBEP)
Number of subjects: 31
Study 39640300 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit Training Program
Number of subjects: 0
Study 39640300 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39640621 — intervention group
Group type: EXPERIMENTAL
Intervention: Double plasma molecular adsorption system (DPMAS) and low-volume plasma exchange (LPE) on three occasions
Number of subjects: 60
Study 39640621 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving plasma exchange (PE) three times
Number of subjects: 60
Study 39640621 — intervention group
Group type: EXPERIMENTAL
Intervention: DPMAS + LPE
Number of subjects: 60
Study 39640621 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving PE
Number of subjects: 60
Study 39640932 — intervention group
Group type: EXPERIMENTAL
Intervention: WASH
Number of subjects: 1002
Study 39640932 — intervention group
Group type: EXPERIMENTAL
Intervention: IYCF
Number of subjects: 1002
Study 39640932 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 1002
Study 39640932 — intervention group
Group type: COMPARATOR
Intervention: Combined WASH & IYCF
Number of subjects: 1002
Study 39640961 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMO-AI using images from a 12.2 megapixel camera
Number of subjects: 823
Study 39640961 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMO-AI using images from a Pixel 6 camera
Number of subjects: 823
Study 39640961 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMO-AI with synthetic data supplementation
Number of subjects: 823
Study 39640961 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMO-AI overall detection capability
Number of subjects: 823
Study 39641169 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily avocado consumption
Number of subjects: 0
Study 39641193 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-mFBG PET imaging
Number of subjects: 27
Study 39641307 — intervention group
Group type: EXPERIMENTAL
Intervention: South Asians with T2DM
Number of subjects: 96
Study 39641404 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 25 mg
Number of subjects: 36
Study 39641404 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg
Number of subjects: 36
Study 39641404 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant (both doses)
Number of subjects: 36
Study 39641404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 39641509 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Number of subjects: 74
Study 39641640 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) goggles
Number of subjects: 91
Study 39641640 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 91
Study 39641725 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI with current generation drug-eluting stents (DES)
Number of subjects: 1500
Study 39641725 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1500
Study 39641725 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 1500
Study 39641816 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride (SDF)
Number of subjects: 118
Study 39641816 — intervention group
Group type: COMPARATOR
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 118
Study 39641856 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin (200 mg on day 1, then 100 mg daily)
Number of subjects: 20
Study 39641864 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome analysis using OMNIgene-GUT
Number of subjects: 0
Study 39641926 — intervention group
Group type: EXPERIMENTAL
Intervention: DPYD/UGT1A1 pharmacogenetic-informed therapy
Number of subjects: 563
Study 39641926 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 563
Study 39641985 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help program intervention delivered via an automated conversational agent on WhatsApp
Number of subjects: 1345
Study 39641985 — intervention group
Group type: COMPARATOR
Intervention: Active control group with access to evidence-based wellness resources available online
Number of subjects: 1345
Study 39642162 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-depleted evening light environment
Number of subjects: 476
Study 39642162 — intervention group
Group type: COMPARATOR
Intervention: Standard evening light environment
Number of subjects: 476
Study 39642315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitusiran (50 mg or 80 mg)
Number of subjects: 34
Study 39642315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitusiran (AT-based dose regimen)
Number of subjects: 34
Study 39642315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitusiran prophylaxis
Number of subjects: 34
Study 39642329 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote symptom and adherence monitoring app
Number of subjects: 163
Study 39642329 — intervention group
Group type: EXPERIMENTAL
Intervention: App + feedback
Number of subjects: 163
Study 39642329 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 163
Study 39642360 — intervention group
Group type: EXPERIMENTAL
Intervention: Text4Strength (automated text messages)
Number of subjects: 223
Study 39642375 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful breathing
Number of subjects: 51
Study 39642375 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided breathing
Number of subjects: 51
Study 39642375 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath counting
Number of subjects: 51
Study 39642375 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting state
Number of subjects: 51
Study 39642375 — intervention group
Group type: COMPARATOR
Intervention: All breathing training conditions
Number of subjects: 51
Study 39642746 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Inflammatory Index (DII) score
Number of subjects: 582
Study 39642746 — intervention group
Group type: EXPERIMENTAL
Intervention: DII score as a continuous variable
Number of subjects: 582
Study 39642774 — intervention group
Group type: COMPARATOR
Intervention: Lenvatinib plus Pembrolizumab
Number of subjects: 3
Study 39642774 — intervention group
Group type: COMPARATOR
Intervention: Lenvatinib plus Everolimus
Number of subjects: 3
Study 39642774 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 3
Study 39642783 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy with financial incentives (PE+)
Number of subjects: 52
Study 39642783 — intervention group
Group type: COMPARATOR
Intervention: Prolonged Exposure Therapy (PE)
Number of subjects: 52
Study 39642783 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 52
Study 39642889 — intervention group
Group type: EXPERIMENTAL
Intervention: EZH2 inhibitors
Number of subjects: 0
Study 39642902 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of autologous gene-corrected haematopoietic stem cells
Number of subjects: 8
Study 39642938 — intervention group
Group type: EXPERIMENTAL
Intervention: ElderTree intervention
Number of subjects: 346
Study 39642938 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 346
Study 39643110 — intervention group
Group type: EXPERIMENTAL
Intervention: Count of neonatal morbidities (Serious brain injury, Bronchopulmonary dysplasia, Severe retinopathy of prematurity)
Number of subjects: 3794
Study 39643207 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided PCI
Number of subjects: 1639
Study 39643207 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1639
Study 39643644 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold acclimation with shivering
Number of subjects: 15
Study 39643869 — intervention group
Group type: EXPERIMENTAL
Intervention: SWELE program (16-week program combining unstructured outdoor play activities with mindfulness-based interventions)
Number of subjects: 0
Study 39644340 — intervention group
Group type: COMPARATOR
Intervention: Functional bandage (n=51)
Number of subjects: 113
Study 39644340 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-restraint measures (n=62)
Number of subjects: 113
Study 39644455 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 s-STS
Number of subjects: 376
Study 39644455 — intervention group
Group type: EXPERIMENTAL
Intervention: 5r-STS
Number of subjects: 376
Study 39644455 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 30 s-STS and 5r-STS
Number of subjects: 376
Study 39644535 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI-FUDR (Hepatic Arterial Infusion of Floxuridine)
Number of subjects: 92
Study 39644535 — intervention group
Group type: COMPARATOR
Intervention: Standard systemic chemotherapy only (non-HAI group)
Number of subjects: 92
Study 39644858 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatic solution (lavender and ginger oil) applied as a mouth spray at 0, 2, 4, 6, and 8 hours postoperatively
Number of subjects: 110
Study 39644858 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouth spray
Number of subjects: 110
Study 39644858 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 110
Study 39644890 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS to the left dorsolateral prefrontal cortex (dlPFC)
Number of subjects: 241
Study 39644890 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation to the left dorsolateral prefrontal cortex (dlPFC)
Number of subjects: 241
Study 39644907 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitapivat 50 mg
Number of subjects: 79
Study 39644907 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitapivat 100 mg
Number of subjects: 79
Study 39644907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 39644913 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI plus TAVI
Number of subjects: 172
Study 39644913 — intervention group
Group type: COMPARATOR
Intervention: SAVR plus CABG
Number of subjects: 172
Study 39645016 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotatercept (activin signaling inhibitor)
Number of subjects: 429
Study 39645016 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotatercept
Number of subjects: 429
Study 39645140 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) of the Nucleus Accumbens (NAc)
Number of subjects: 6
Study 39645178 — intervention group
Group type: EXPERIMENTAL
Intervention: PAMM in A-AION
Number of subjects: 32
Study 39645178 — intervention group
Group type: COMPARATOR
Intervention: Peripapillary IRF/SRF in NA-AION
Number of subjects: 32
Study 39645178 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined biomarkers
Number of subjects: 32
Study 39645236 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib, Venetoclax, and Obinutuzumab (AVO)
Number of subjects: 72
Study 39645254 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF with assessment of niche presence via SHG and TVS
Number of subjects: 250
Study 39645257 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS-based NFT in a VR classroom setting
Number of subjects: 138
Study 39645257 — intervention group
Group type: COMPARATOR
Intervention: Conventional computerised cognitive training (active control)
Number of subjects: 138
Study 39645257 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 138
Study 39645270 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of β-blocker therapy
Number of subjects: 2540
Study 39645270 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of β-blocker therapy
Number of subjects: 2540
Study 39645388 — intervention group
Group type: EXPERIMENTAL
Intervention: Community walking and home-based circuit training programme
Number of subjects: 34
Study 39647171 — intervention group
Group type: EXPERIMENTAL
Intervention: BNC210
Number of subjects: 182
Study 39647171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 39647248 — intervention group
Group type: EXPERIMENTAL
Intervention: P3 intervention (text-messages linking to animated videos)
Number of subjects: 104
Study 39647248 — intervention group
Group type: COMPARATOR
Intervention: Control (patient education webpages)
Number of subjects: 104
Study 39647248 — intervention group
Group type: EXPERIMENTAL
Intervention: P3 fathers
Number of subjects: 104
Study 39647248 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents who viewed the video on fathers' rights
Number of subjects: 104
Study 39647263 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate (HC) diet
Number of subjects: 30
Study 39647263 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (LC) diet
Number of subjects: 30
Study 39647494 — intervention group
Group type: EXPERIMENTAL
Intervention: MenABCWY (two doses at months 0 and 6)
Number of subjects: 3651
Study 39647494 — intervention group
Group type: EXPERIMENTAL
Intervention: MenABCWY
Number of subjects: 3651
Study 39647494 — intervention group
Group type: COMPARATOR
Intervention: 4CMenB (two doses at months 0 and 6)
Number of subjects: 3651
Study 39647494 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-CRM (one dose at month 0)
Number of subjects: 3651
Study 39647798 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 0
Study 39647798 — intervention group
Group type: COMPARATOR
Intervention: Placebo (standard-of-care antibiotics)
Number of subjects: 0
Study 39647797 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg subcutaneously once daily for 10 days
Number of subjects: 992
Study 39647999 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 0
Study 39647999 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine and Rituximab
Number of subjects: 0
Study 39648069 — intervention group
Group type: EXPERIMENTAL
Intervention: Class II occlusion group (study group)
Number of subjects: 37
Study 39648069 — intervention group
Group type: COMPARATOR
Intervention: Control group (neutral occlusion)
Number of subjects: 37
Study 39648069 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group of participants
Number of subjects: 37
Study 39648079 — intervention group
Group type: EXPERIMENTAL
Intervention: Chef-ID intervention (12-week program including weekly group sessions for cooking skills, nutrition education, and exercise)
Number of subjects: 0
Study 39648079 — intervention group
Group type: EXPERIMENTAL
Intervention: Chef-ID intervention
Number of subjects: 0
Study 39648196 — intervention group
Group type: EXPERIMENTAL
Intervention: Hernia Blocking System (HBS) implanted after limited discectomy
Number of subjects: 30
Study 39648217 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib plus chemotherapy
Number of subjects: 91
Study 39648226 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrotinib
Number of subjects: 1071
Study 39648226 — intervention group
Group type: EXPERIMENTAL
Intervention: metabolic pathway-related gene mutations
Number of subjects: 1071
Study 39648226 — intervention group
Group type: EXPERIMENTAL
Intervention: decreased or achieved early clearance of ctDNA after the initial two treatment cycles
Number of subjects: 1071
Study 39648226 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy, endocrine therapy, or CDK4/6 inhibitor therapy
Number of subjects: 1071
Study 39648235 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting for spinal arthrodesis
Number of subjects: 15
Study 39648279 — intervention group
Group type: EXPERIMENTAL
Intervention: Therakos CELLEX
Number of subjects: 20
Study 39648279 — intervention group
Group type: COMPARATOR
Intervention: Amicus ECP system
Number of subjects: 20
Study 39648559 — intervention group
Group type: EXPERIMENTAL
Intervention: BLV 2 mg
Number of subjects: 269
Study 39648559 — intervention group
Group type: EXPERIMENTAL
Intervention: BLV 10 mg
Number of subjects: 269
Study 39648559 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon-alfa
Number of subjects: 269
Study 39648559 — intervention group
Group type: COMPARATOR
Intervention: Control (delayed treatment group)
Number of subjects: 269
Study 39648614 — intervention group
Group type: EXPERIMENTAL
Intervention: Islatravir 60 mg single oral dose
Number of subjects: 14
Study 39648614 — intervention group
Group type: COMPARATOR
Intervention: Standard methadone therapy
Number of subjects: 14
Study 39648617 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg once-daily
Number of subjects: 0
Study 39648617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39648629 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant
Number of subjects: 5
Study 39648629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 39648796 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily chicken egg intake for 6 months
Number of subjects: 500